Effects of Royal Jelly on Gut Dysbiosis and NAFLD in db/db Mice
Nutrients · 2023
DOI: 10.3390/nu15112580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Genki Kobayashi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yamada Bee Company, Inc..
Abstract (Originalsprache)
Royal jelly (RJ) is a naturally occurring substance synthesized by honeybees and has various health benefits. Herein, we focused on the medium-chain fatty acids (MCFAs) unique to RJ and evaluated their therapeutic efficacy in treating non-alcoholic fatty liver disease (NAFLD). We examined db/m mice that were exclusively fed a normal diet, db/db mice exclusively fed a normal diet, and db/db mice fed varying RJ quantities (0.2, 1, and 5%). RJ improved NAFLD activity scores and decreased gene expression related to fatty acid metabolism, fibrosis, and inflammation in the liver. RJ regulated innate immunity-related inflammatory responses in the small intestine and decreased the expression of genes associated with inflammation and nutrient absorption transporters. RJ increased the number of operational taxonomic units, the abundance of Bacteroides, and seven taxa, including bacteria that produce short-chain fatty acids. RJ increased the concentrations of RJ-related MCFAs (10-hidroxy-2-decenoic acid, 10-hydroxydecanoic acid, 2-decenedioic acid, and sebacic acid) in the serum and liver. These RJ-related MCFAs decreased saturated fatty acid deposition in HepG2 cells and decreased the gene expression associated with fibrosis and fatty acid metabolism. RJ and RJ-related MCFAs improved dysbiosis and regulated the expression of inflammation-, fibrosis-, and nutrient absorption transporter-related genes, thereby preventing NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
- Metabologenomics Inc., Tsuruoka 997-0052, Japan.
- Department of Life Science and Technology, Tokyo Institute of Technology, Tokyo 152-8550, Japan.
- Institute for Health Science, R&D Department, Yamada Bee Company, Inc., Okayama 708-0393, Japan.
- AiSTI SCIENCE Co., Ltd., Wakayama 640-0033, Japan.
ORCID-Profile: Takuro Okamura, Hiroshi Okada, Emi Ushigome, Yuichiro Nishimoto, Hideto Okamoto, Nobuaki Okumura, Masahide Hamaguchi, Michiaki Fukui
Förderung
- Yamada Bee Company, Inc.
Zitieren
APA
Kobayashi, G., Okamura, T., Majima, S., Senmaru, T., Okada, H., Ushigome, E., Nakanishi, N., Nishimoto, Y., Yamada, T., Okamoto, H., Okumura, N., Sasano, R., Hamaguchi, M., & Fukui, M. (2023). Effects of Royal Jelly on Gut Dysbiosis and NAFLD in db/db Mice. Nutrients. https://doi.org/10.3390/nu15112580
Vancouver
Kobayashi G, Okamura T, Majima S, Senmaru T, Okada H, Ushigome E, et al. Effects of Royal Jelly on Gut Dysbiosis and NAFLD in db/db Mice. Nutrients. 2023. doi:10.3390/nu15112580
BibTeX
@article{Kobayashi2023,
author = {Kobayashi, Genki and Okamura, Takuro and Majima, Saori and Senmaru, Takafumi and Okada, Hiroshi and Ushigome, Emi and Nakanishi, Naoko and Nishimoto, Yuichiro and Yamada, Takuji and Okamoto, Hideto and Okumura, Nobuaki and Sasano, Ryoichi and Hamaguchi, Masahide and Fukui, Michiaki},
title = {Effects of Royal Jelly on Gut Dysbiosis and NAFLD in db/db Mice},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15112580}
}
EUVIMED